HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 425 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.31 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $912 | +14.6% | 23,869 | +8.2% | 0.01% | +25.0% |
| Q2 2023 | $796 | -92.3% | 22,069 | -91.9% | 0.00% | -93.3% |
| Q1 2023 | $10,390 | +783.5% | 272,069 | +1216.3% | 0.06% | +757.1% |
| Q4 2022 | $1,176 | -99.9% | 20,669 | 0.0% | 0.01% | +40.0% |
| Q3 2022 | $817,000 | -10.1% | 20,669 | 0.0% | 0.01% | -16.7% |
| Q2 2022 | $909,000 | -3.3% | 20,669 | -12.3% | 0.01% | +20.0% |
| Q1 2022 | $940,000 | -17.9% | 23,569 | -17.2% | 0.01% | -16.7% |
| Q4 2021 | $1,145,000 | -1.1% | 28,469 | 0.0% | 0.01% | 0.0% |
| Q3 2021 | $1,158,000 | -10.4% | 28,469 | 0.0% | 0.01% | -14.3% |
| Q2 2021 | $1,293,000 | +32.2% | 28,469 | +21.3% | 0.01% | +16.7% |
| Q1 2021 | $978,000 | -25.1% | 23,469 | -23.2% | 0.01% | -25.0% |
| Q4 2020 | $1,306,000 | +21.9% | 30,569 | -25.0% | 0.01% | 0.0% |
| Q3 2020 | $1,071,000 | -51.0% | 40,769 | -50.0% | 0.01% | -11.1% |
| Q2 2020 | $2,186,000 | – | 81,538 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |